Obesity drug sales help Novo Nordisk beat expectations
Sales of Novo Nordisk’s obesity drug, Wegovy, rose by more than 50 per cent last year, helping the Danish drugmaker beat revenue expectations. The company on Wednesday reported that net sales increased by 26 per cent year on year in 2024 to DKr290bn ($40bn),
Cost is a major obstacle for many. The drugs can be expensive without insurance, with out-of-pocket expenses reaching ...
Ozempic is primarily used for managing type 2 ... though it’s not a weight loss medication. Starting dose: 0.25 mg weekly for 4 weeks. Gradually increased to a maximum dose of 2.0 mg weekly.
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
The Food and Drug Administration has approved Ozempic ® (semaglutide) to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, and cardiovascular ...
The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." ...
960 The Ref on MSN7d
FDA approves Ozempic to reduce risk of kidney disease progression, cardiovascular deathThe Food and Drug Administration approved Ozempic to be used to lessen the risk of kidney disease from getting worse, ...
“The type of food GLP-1 users want changes; their tastebuds change,” says New York-based physician Dr Alexandra Sowa, author of The Ozempic Revolution (HarperCollins, £25). “People crave ...
Its highly-anticipated iPhone model will be 2 millimeters thinner than existing models — a decrease of roughly 25%, per Bloomberg, which cheekily likened devices of the skinny phone trend to Ben ...
14hon MSN
Novo’s newest GLP-1, CagriSema, is the first big test of Novo Nordisk’s future as the leader in the obesity treatment market.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback